Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rehan Ali

Interventional Pain Medicine Ridgewood, NJ Medical Doctor

NPI 1144527011 CMS profile 1340150

1144 E Ridgewood Ave Fl 2, Fl 2, Ridgewood, NJ 07450

Open in the dashboard

General payments

$5,708

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rehan Ali of Ridgewood, NJ is reported in the CMS Open Payments database as having received $5,708 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $469 22
2024 General $946 52
2023 General $513 21
2022 General $189 4
2021 General $281 20
2020 General $599 16
2019 General $2,712 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rehan Ali
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Rehan Ali were reported at $469. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Rehan Ali Interventional Pain Medicine median Middle half National median
2019 $2,712 $684 $216–$2,079 $163
2020 $599 $382 $122–$1,109 $114
2021 $281 $552 $167–$1,554 $132
2022 $189 $605 $187–$1,924 $149
2023 $513 $671 $195–$1,915 $160
2024 $946 $684 $206–$1,837 $164
2025 $469 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $2,030 8 payments
  2. Vertos Medical, Inc. $900 28 payments
  3. BIOTRONIK NRO, Inc. $826 50 payments
  4. Boston Scientific Corporation $756 37 payments
  5. Medtronic, Inc. $376 12 payments
  6. Abbott Laboratories $292 10 payments
  7. Nevro Corp. $182 3 payments
  8. DePuy Synthes Sales Inc. $87 4 payments
  9. SPR Therapeutics, Inc $81 1 payment
  10. Merck Sharp & Dohme Corporation $41 3 payments
  11. Other $137 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,847 160 payments
  2. Travel and Lodging $1,861 4 payments
Products named General payments · program years 2019–2025
  1. ClosureFast $2,030 8 payments
  2. mild Device Kit Orthopedic $564 24 payments
  3. Prospera Not Applicable $504 30 payments
  4. mild Device Kit Orthopedic $336 4 payments
  5. SPECTRA WAVEWRITER Pain Management $301 9 payments
  6. Prospera Not Applicable $232 16 payments
  7. Proclaim Family of SCS IPGs $165 3 payments
  8. Senza Spinal Cord Stimulation System $163 2 payments
  9. INTELLIS ADAPTIVESTIM $161 7 payments
  10. SPECTRA WAVEWRITER Spectra Wavewriter $138 6 payments
  11. Other $1,112 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

124

Median for Pain Management: 951

Drug cost

$890

Median for Pain Management: $26,034

Branded share of claims

34.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 43 $272
Pregabalin Generic 11 $173
Oxycodone Hcl Generic 13 $135
Tramadol Hcl Generic 24 $128
Cyclobenzaprine Hcl Generic 17 $118
Gabapentin Generic 16 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$41,366

Of which drugs: $420

Medicare patients

72

Average age 70

Services billed

503

44 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Diabetes 33%
Depression 31%
Ischemic heart disease 29%
COPD 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 23 144 $111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record